Diovan HCT valsartan/hydrochlorothiazide regulatory update

FDA approved an sNDA from Novartis to extend the label for Diovan HCT valsartan/hydrochlorothiazide to include use as first-line treatment of hypertension. The combination angiotensin receptor blocke...